239 related articles for article (PubMed ID: 22155506)
21. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma.
Kanakry JA; Kasamon YL; Gocke CD; Tsai HL; Davis-Sproul J; Ghosh N; Symons H; Bolaños-Meade J; Gladstone DE; Swinnen LJ; Luznik L; Fuchs EJ; Jones RJ; Ambinder RF
Biol Blood Marrow Transplant; 2013 Apr; 19(4):602-6. PubMed ID: 23370119
[TBL] [Abstract][Full Text] [Related]
22. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
23. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.
Kanate AS; Mussetti A; Kharfan-Dabaja MA; Ahn KW; DiGilio A; Beitinjaneh A; Chhabra S; Fenske TS; Freytes C; Gale RP; Ganguly S; Hertzberg M; Klyuchnikov E; Lazarus HM; Olsson R; Perales MA; Rezvani A; Riches M; Saad A; Slavin S; Smith SM; Sureda A; Yared J; Ciurea S; Armand P; Salit R; Bolaños-Meade J; Hamadani M
Blood; 2016 Feb; 127(7):938-47. PubMed ID: 26670632
[TBL] [Abstract][Full Text] [Related]
24. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.
Duléry R; Mohty M; Duhamel A; Robin M; Beguin Y; Michallet M; Vigouroux S; Lioure B; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Daguindau E; Ceballos P; Clément L; Dauriac C; Maillard N; Legrand F; Cornillon J; Guillerm G; François S; Lapusan S; Chevallier P; Damaj G; Yakoub-Agha I
Biol Blood Marrow Transplant; 2014 May; 20(5):646-54. PubMed ID: 24462982
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
[TBL] [Abstract][Full Text] [Related]
26. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
27. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
28. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
29. Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.
Nakamae H; Storer BE; Storb R; Storek J; Chauncey TR; Pulsipher MA; Petersen FB; Wade JC; Maris MB; Bruno B; Panse J; Petersdorf E; Woolfrey A; Maloney DG; Sandmaier BM
Biol Blood Marrow Transplant; 2010 Mar; 16(3):384-94. PubMed ID: 19900571
[TBL] [Abstract][Full Text] [Related]
30. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
[TBL] [Abstract][Full Text] [Related]
31. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
32. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.
Burroughs LM; O'Donnell PV; Sandmaier BM; Storer BE; Luznik L; Symons HJ; Jones RJ; Ambinder RF; Maris MB; Blume KG; Niederwieser DW; Bruno B; Maziarz RT; Pulsipher MA; Petersen FB; Storb R; Fuchs EJ; Maloney DG
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1279-87. PubMed ID: 18940683
[TBL] [Abstract][Full Text] [Related]
33. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.
van Besien K; Carreras J; Bierman PJ; Logan BR; Molina A; King R; Nelson G; Fay JW; Champlin RE; Lazarus HM; Vose JM; Hari PN
Biol Blood Marrow Transplant; 2009 May; 15(5):554-63. PubMed ID: 19361747
[TBL] [Abstract][Full Text] [Related]
34. Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
McClune BL; Ahn KW; Wang HL; Antin JH; Artz AS; Cahn JY; Deol A; Freytes CO; Hamadani M; Holmberg LA; Jagasia MH; Jakubowski AA; Kharfan-Dabaja MA; Lazarus HM; Miller AM; Olsson R; Pedersen TL; Pidala J; Pulsipher MA; Rowe JM; Saber W; van Besien KW; Waller EK; Aljurf MD; Akpek G; Bacher U; Chao NJ; Chen YB; Cooper BW; Dehn J; de Lima MJ; Hsu JW; Lewis ID; Marks DI; McGuirk J; Cairo MS; Schouten HC; Szer J; Ramanathan M; Savani BN; Seftel M; Socie G; Vij R; Warlick ED; Weisdorf DJ
Biol Blood Marrow Transplant; 2014 Jul; 20(7):960-8. PubMed ID: 24641829
[TBL] [Abstract][Full Text] [Related]
35. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
Devetten MP; Hari PN; Carreras J; Logan BR; van Besien K; Bredeson CN; Freytes CO; Gale RP; Gibson J; Giralt SA; Goldstein SC; Gupta V; Marks DI; Maziarz RT; Vose JM; Lazarus HM; Anderlini P
Biol Blood Marrow Transplant; 2009 Jan; 15(1):109-17. PubMed ID: 19135949
[TBL] [Abstract][Full Text] [Related]
36. Influence of HLA 1-3-locus mismatch and antithymocyte globulin administration in unrelated bone marrow transplantation.
Kawamura K; Kanda J; Ohashi K; Fukuda T; Iwato K; Eto T; Fujiwara SI; Mori T; Fukushima K; Ozawa Y; Uchida N; Ashida T; Ichinohe T; Atsuta Y; Kanda Y
Ann Hematol; 2020 May; 99(5):1099-1110. PubMed ID: 32206853
[TBL] [Abstract][Full Text] [Related]
37. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
38. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
39. Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.
Nagler A; Labopin M; Dholaria B; Niittyvuopio R; Maertens J; Poiré X; Cornelissen J; Reményi P; Bourhis JH; Beguin Y; Malladi R; Kerre T; Schroyens W; Savani BN; Mohty M
Blood Adv; 2019 Jul; 3(13):1950-1960. PubMed ID: 31262738
[TBL] [Abstract][Full Text] [Related]
40. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Mohty M; Bay JO; Faucher C; Choufi B; Bilger K; Tournilhac O; Vey N; Stoppa AM; Coso D; Chabannon C; Viens P; Maraninchi D; Blaise D
Blood; 2003 Jul; 102(2):470-6. PubMed ID: 12649133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
